Navigation Links
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Date:8/14/2008

p>

--------------------------

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $51,048,837 $68,745,694

Short-term investments 987,126 1,252,113

Amounts due under collaborative agreements 1,863,843 919,110

Prepaid expenses and other assets 1,189,002 783,311

--------------------------

Total current assets 55,088,808 71,700,228

--------------------------

EQUIPMENT AND LEASEHOLD IMPROVEMENTS:

Laboratory, office furniture and equipment 3,240,023 2,462,647

Leasehold improvements 1,836,553 1,836,553

--------------------------

5,076,576 4,299,200

Less accumulated depreciation and amortization (2,185,498) (1,437,080)

--------------------------

Total equipment and leasehold

improvements, net 2,891,078 2,862,120

OTHER ASSETS 249,875 1,282,051

--------------------------

TOTAL $58,229,761 $75,844,399

==========================

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Current portion of long-term debt $1,167,289 $-

Current portion of capital lease obligation 82,558 159,440

Accounts payable 1,314,299 3,281,600

Accrued expenses
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmasset Receives Notice of Allowance
4. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
5. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
6. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2008)...dy finds the majority of acute lymphoblastic leuke...t at the time of diagnosis , , MEMPHIS, Ten...at St. Jude Children,s Research Hospital have iden...ells of children with acute lymphoblastic leukemia...thway to designing treatments for ALL relapse in c...
(Date:11/26/2008)...ed information density, automation and intelligent... ultrasound to an all new level , , CHICAGO... Healthcare ( www.siemens.com/healthcare ) hig...me Scanner (ABVS)(1), the world,s first multi-use...e 94th Scientific Assembly and Annual Meeting of t...
(Date:11/25/2008)... awareness can improve recovery , , Audio a... available on the Mayo Clinic News Blog. Please se... , ROCHESTER, Minn., Nov. 25 /PRNewswire-USNe... stroke patients don,t think they,re having a stro...ntil their condition worsens. The findings appear ...
(Date:11/25/2008)... reveal most respondents against expanding statin ..., LITTLE FALLS, N.J., Nov. 25 JU...y lower the cardiovascular risk of healthy patient...tatin use in older adults, according to a national... participants took part in the online poll conduct...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Strawberry fields ripe for the picking 1486 1Strawberry fields ripe for the picking 1486 2Making emergency artery repair safer 7749 1Jury Awards 245 25 Million Malpractice Verdict Against Fort Worth Doctor 7745 1Jury Awards 245 25 Million Malpractice Verdict Against Fort Worth Doctor 7745 2Blue Cross Foundation Invests in Community Health 7741 1Blue Cross Foundation Invests in Community Health 7741 2Blue Cross Foundation Invests in Community Health 7741 3Blue Cross Foundation Invests in Community Health 7741 4
...007 /PRNewswire-FirstCall/ --,Phosphagenics Limite... pre-clinical studies of its TPM-02 dermal drug de... leading topical,treatment for severe acne and an ...The proof of concept studies showed a three-fold i...nto the skin when formulated,with TPM-02 compared ...
...ewswire-USNewswire/ -- Childhood,cancers are fortu...ecial case, accounting for 7 percent of all childh...aths. It typically occurs as a,solid tumor in the ...developing in the network of the body,s sympatheti...ns call a heterogeneous disease;,its name includes...
Other Medicine Technology:Phosphagenics Announces Positive Proof of Concept Results from,Studies Utilizing Company's Dermal Drug Delivery Technology 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 2Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer 3
(Date:12/1/2008)...wire-FirstCall/ -- The Ensign Group, Inc.,(Nasdaq... Rehabilitation Center in,Pocatello, Idaho has su... and,Medicaid Services, Special Focus program. ,...h/20071213/LATH168LOGO ) , A clinical team ...llo Care,& Rehabilitation Center, completed t...
(Date:12/1/2008)..., at Memorial Sloan-Kettering Cancer Center, New Y... expression of genes for therapeutic purposes, and... in mice. , Small, noncoding RNA molecules known... expression. In the study, the miRNA miR-181a was ...ne cells known as T cells at different stages of t...
(Date:12/1/2008)...irstCall/ -- ViroPharma Incorporated,(Nasdaq: V... supplemental,Biologics License Application (sBLA...for Cinryze(TM) C1 Inhibitor (human) as a treatmen...). , The sBLA is based on a re-analysis and...e treatment study of Cinryze and interim data from...
(Date:12/1/2008)...ty illnesses common, study shows , , MO...ders are common among young adults in the United S... , To reach this finding, U.S. researchers anal...9 to 25, who took part in the National Epidemiolog...The study found that 45.8 percent of the 2,188 col...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...der unsanitary and freezing conditions in the coun...e and shell marine products.// The National Instit...bad conducted a study which reveals that many amon...n working in fish processing units are predominant...
...d that more devastating earthquakes are likely to ...50 years. // They will inflict far greater damage ... in Pakistan. Roger Bilham who has been working i... the past two months, said that a huge amount of e...
... Journal of Psychiatry that antidepressant drugs d...rather decrease the suicide risk. The article also...nt drugs should be closely monitored to find their... dosage can cause adverse conditions. The resea...
...nd news media to increase the awareness about chil...// to increase child survival. The Lancet reports ...achievable, Millennium Development Goal – 4 (MDG) ...en below the age of 5 and MDG-5 wants a reduction ...
Other Medicine News:Health News:Unregulated Fish Industry Harms Health Of Women 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre
Economy Apron, Excellent Protection, Value Priced
Surgical Drop-Off Apron
All Day Comfort for the Lower Body
Medicine Products: